Cheng Du Sheng Nuo Biotec Co. Ltd. A Total Liabilities
Cheng Du Sheng Nuo Biotec Co. Ltd. A total liabilities. Based on the latest financial reports, Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has total liabilities worth CN¥877.24 Million CNY (≈ $128.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Cheng Du Sheng Nuo Biotec Co. Ltd. A to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
Total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024. This chart illustrates how Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.
Cheng Du Sheng Nuo Biotec Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Cheng Du Sheng Nuo Biotec Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kambi Group Plc
F:7KB
|
Germany | €37.87 Million |
|
RFG Holdings Ltd
JSE:RFG
|
South Africa | ZAC2.14 Billion |
|
Beijing Hanbang Technology Corp
SHE:300449
|
China | CN¥157.86 Million |
|
Guggenheim Taxable Municipal Managed Duration Trust
NYSE:GBAB
|
USA | $175.71 Million |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
USA | $28.12 Million |
|
Qumei Furniture Group Co Ltd
SHG:603818
|
China | CN¥3.88 Billion |
|
SPCG Public Company Limited
BK:SPCG
|
Thailand | ฿367.68 Million |
|
Zoneco Group Co Ltd
SHE:002069
|
China | CN¥2.16 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Cheng Du Sheng Nuo Biotec Co. Ltd. A asset portfolio.
Liquidity & Leverage Metrics
Cheng Du Sheng Nuo Biotec Co. Ltd. A Total Liabilities Ratios Explained
Cheng Du Sheng Nuo Biotec Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cheng Du Sheng Nuo Biotec Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2017–2024)
The table below shows the annual total liabilities of Cheng Du Sheng Nuo Biotec Co. Ltd. A from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥729.58 Million ≈ $106.76 Million |
+67.48% |
| 2023-12-31 | CN¥435.63 Million ≈ $63.75 Million |
+54.88% |
| 2022-12-31 | CN¥281.27 Million ≈ $41.16 Million |
+64.03% |
| 2021-12-31 | CN¥171.48 Million ≈ $25.09 Million |
+10.34% |
| 2020-12-31 | CN¥155.41 Million ≈ $22.74 Million |
+9.09% |
| 2019-12-31 | CN¥142.46 Million ≈ $20.85 Million |
-5.59% |
| 2018-12-31 | CN¥150.90 Million ≈ $22.08 Million |
+41.74% |
| 2017-12-31 | CN¥106.46 Million ≈ $15.58 Million |
-- |
About Cheng Du Sheng Nuo Biotec Co. Ltd. A
ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more